Adverum Biotechnologies to Participate in Piper Jaffray’s 31st Annual Healthcare Conference
November 20 2019 - 4:01PM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene
therapy company targeting unmet medical needs in ocular and rare
diseases, today announced that the company will present at
Piper Jaffray’s 31st Annual Healthcare Conference on Wednesday,
December 4, 2019 at 11:00 am EST.
A live audio webcast will be accessible under Events and
Presentations in the Investors section of the company's website.
The archived audio webcast will be available on the Adverum website
following the presentation for 30 days.
About Adverum
Biotechnologies, Inc. Adverum
Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene
therapy company targeting unmet medical needs for serious ocular
and rare diseases. Adverum is evaluating its novel gene therapy
candidate, ADVM-022, as a one-time, intravitreal injection for the
treatment of its lead indication, wet age-related macular
degeneration. For more information, please
visit www.adverum.com.
Investor and Media Inquiries:
Investors: Myesha Lacy Adverum Biotechnologies Vice President,
Investor Relations and Corporate Communications mlacy@adverum.com
1-650-304-3892
Media: Cherilyn Cecchini, M.D. Account Supervisor
ccecchini@lifescipublicrelations.com 1-646-876-5196
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2023 to Apr 2024